menu
    • menu

    Orion Corporation's list of EU CTD Dossiers, Marketing Authorizations, In, Out Licensing Opportunities & Finished Dosage Formulations (FDF) aggregated by PharmaCompass

    Fermion-PSE
    News
    Science Based Targets Initiative approves Orion’s Climate Targets

    30 Sep 2024

    // GLOBENEWSWIRE

    Orion's Partner Bayer Submits Application For Darolutamide

    26 Sep 2024

    // GLOBENEWSWIRE

    Orion And Aitia Enter AI Drug Discovery Collaboration

    25 Sep 2024

    // PR NEWSWIRE

    DATA COMPILATION
    #PharmaFlow

    Fermion

    Contact Supplier

    Website

    Discovery on Target

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics, etc.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Orion CorporationFinland Flag
    Country
    Country
    Finland
    Address
    Address
    Head officeOrion CorporationOrionintie 1A, FI-02200 Espoo, FinlandP.O.Box 65, ...
    Telephone
    Telephone
    +358 10 4261
    Client Email
    Email
    fermionSales@fermion.fi
    Client Website
    Website
    https://www.orion.fi/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/orion-corporation/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPhI Worldwide, Milan

    CPhI Worldwide, Milan

    Not Confirmed

    envelop Contact Supplier

    CPhI Worldwide, Milan

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    Science Based Targets Initiative approves Orion’s Climate Targets
    Science Based Targets Initiative approves Orion’s Climate Targets

    30 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2024/09/30/2954893/0/en/Orion-s-near-term-climate-targets-approved-by-the-Science-Based-Targets-initiative.html

    GLOBENEWSWIRE
    30 Sep 2024
    Share Share
    Orion's Partner Bayer Submits Application For Darolutamide
    Orion's Partner Bayer Submits Application For Darolutamide

    26 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/26/2953537/0/en/Orion-s-collaboration-partner-Bayer-submits-application-to-U-S-FDA-for-third-indication-of-darolutamide-which-has-become-the-first-ever-Orion-originated-blockbuster.html

    GLOBENEWSWIRE
    26 Sep 2024
    Share Share
    Orion And Aitia Enter AI Drug Discovery Collaboration
    Orion And Aitia Enter AI Drug Discovery Collaboration

    25 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orion-and-aitia-enter-ai-driven-drug-discovery-and-drug-simulation-collaboration-in-oncology-302258493.html

    PR NEWSWIRE
    25 Sep 2024
    Share Share
    213,285 Orion Corporation A shares converted into B shares
    213,285 Orion Corporation A shares converted into B shares

    20 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/20/2949488/0/en/213-285-Orion-Corporation-A-shares-converted-into-B-shares.html

    GLOBENEWSWIRE
    20 Sep 2024
    Share Share
    Darolutamide Plus ADT Reduces Prostate Cancer Progression
    Darolutamide Plus ADT Reduces Prostate Cancer Progression

    16 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/16/2946403/0/en/Darolutamide-plus-androgen-deprivation-therapy-significantly-reduced-the-risk-of-radiological-progression-or-death-by-46-compared-to-placebo-plus-ADT-in-patients-with-metastatic-ho.html

    GLOBENEWSWIRE
    16 Sep 2024
    Share Share
    Inside information: Orion upgrades full-year outlook for 2024
    Inside information: Orion upgrades full-year outlook for 2024

    11 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/11/2944256/0/en/Inside-information-Orion-upgrades-full-year-outlook-for-2024.html

    GLOBENEWSWIRE
    11 Sep 2024
    Share Share

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search